Protocol amendments now affect 76% of trials, up from 57% in 2015, with each Phase III substantial amendment costing an average of $535,000 in direct expenses. The deeper problem isn't writing quality, it's knowledge consistency: when eligibility criteria in your protocol don't match your ICF, or your DSUR uses different adverse event terms than your IB, you face regulatory risk, delayed IRB approvals, and potential participant safety concerns. KScribe addresses this through what Kitsa calls structured clinical intelligence, parsing trial source inputs into a shared knowledge model before generating any document. Every protocol fact, from age thresholds to dosing schedules, exists as a single canonical entity. When a Phase II protocol amends minimum enrollment age from 18 to 21, that change automatically flags every affected section across the ICF, IB, DSUR, and CSR, rather than relying on manual cross-referencing. This aligns with ICH E6(R3)'s Quality by Design framework, which requires sponsors to proactively design quality into trials and maintain consistency through the entire lifecycle. The approach shifts document review from detecting errors to confirming alignment with the underlying trial model.